No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
EXAS240517P80000
- 7.70
- 0.000.00%
15min DelayTrading Apr 9 15:38 ET
0.00High0.00Low
0.00Open7.70Pre Close0 Volume0 Open Interest80.00Strike Price0.00Turnover96.68%IV-0.85%PremiumMay 17, 2024Expiry Date19.94Intrinsic Value100Multiplier9DDays to Expiry0.00Time Value100Contract SizeAmericanOptions Type-0.9690Delta0.0096Gamma2.94Leverage Ratio-0.0256Theta-0.0093Rho-2.85Eff Leverage0.0065Vega
Intraday
- 5D
- 1D
News
Stocks Falter As Fed Signals Need For Higher-For-Longer Rates; Uber Crashes, Energy Sector Loses Ground: What's Driving Wednesday's Market?
Wednesday witnessed a tempering of the bullish sentiment that had buoyed Wall Street in recent sessions, with major indices showing slight declines around midday trading in New York.Hawkish remarks fr
Wall Street Poised For Muted Open On Mixed Earnings, With More Fed Speeches In Store: Analyst Sees S&P 500 Crossing Late-March High
U.S. stocks are on track for a mixed start on Wednesday as the market digests mixed earnings reports and looks ahead to more speeches by Federal Reserve officials. Given the paucity of any market-movi
Exact Sciences: Maintaining Market Dominance With Cologuard Amid Emerging Competition
Exact Sciences Demonstrates Continued Scientific Advancement in Colorectal Cancer Screening With Multiple Data Presentations at DDW 2024
MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, announced today the company will present six abstracts on strategies a
LabCorp Partner Geneoscopy Wins FDA Approval of Colorectal Cancer Test ColoSense
Will Earnings Cheer Continue This Week? All Eyes On Disney, Palantir, Robinhood While Reddit Gears Up For Debut Quarterly Report
Earnings reports and a dovish stance from the Federal Reserve lifted stocks last week. Major indices reacted positively, particularly to earnings from high-profile companies that hold significant weig
Comments
Exact Sciences' progress has failed to meet high market expectations, yet its consistent revenue growth suggests it may be worth further investigation. The company's performance has underperformed the broader market, which gained around 31%.
2
The company's strained balance sheet and lack of EBIT level profitability heighten risk. Its debt management and growth rate are key concerns, with faster growth expected from unprofitable firms.
Exact Sciences' low P/S ratio is due to its poor revenue outlook. Investors foresee limited growth, thus are only willing to pay less for the stock, making a strong share price rise unlikely.
Exact Sciences' growth rate is somewhat slow, showing a 20% rise in revenue while lacking profitability at an EBIT level. Considerable liabilities and negative EBIT results make its financial status seem precarious and risky.
Read more